Anvisa will discuss on April 29 a proposed regulation to govern the manipulation of GLP-1 medications, known as weight loss pens. The measure is part of an action plan announced on April 6 to control the market for these medications.
GLP-1 medications, known as weight-loss pens, include substances like semaglutide, tirzepatide and liraglutide and can currently only be acquired with retained medical prescriptions. The popularization of these medications has expanded the illegal market, including unauthorized compounded versions, raising concerns about health risks to the population.
What the sources say
Click any claim to see the source quotes and primary documents.
Anvisa's board will discuss a proposed normative instruction on weight loss pens on April 29
The new regulation should define procedures for importation, supplier qualification, quality control, storage and transport
Anvisa created working groups with representatives from the Federal Councils of Pharmacy, Medicine and Dentistry
Unconfirmed exclusive
1 source
·
tap to expand
Anvisa published ordinances 488/2026 and 489/2026 creating the working groups
⚠ only one source — exclusive, unconfirmed